Revance Therapeutics traded at $4.67 this Tuesday April 9th, increasing $0.22 or 4.94 percent since the previous trading session. Looking back, over the last four weeks, Revance Therapeutics gained 25.40 percent. Over the last 12 months, its price fell by 85.16 percent. Looking ahead, we forecast Revance Therapeutics to be priced at 4.53 by the end of this quarter and at 4.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.